Research programme: micacocidin analogues - Shionogi

Drug Profile

Research programme: micacocidin analogues - Shionogi

Alternative Names: Micacocidin analogues research programme - Shionogi

Latest Information Update: 09 Jul 2002

Price : $50

At a glance

  • Originator Shionogi
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Mycoplasma infections

Most Recent Events

  • 09 Jul 2002 Discontinued - Preclinical for Mycoplasma infections in Japan (unspecified route)
  • 17 Oct 2001 Preclinical development for Mycoplasma infections in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top